HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Dao M. Nguyen David S. Schrump Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen, D. M. Articles by Roth, S. J. A. Search for Related Content PubMed PubMed Citation Articles by Nguyen, D. M. Articles by Roth, S. J. A.

J Thorac Cardiovasc Surg 1999;118:908-915
© 1999 Mosby, Inc.

GENERAL THORACIC SURGERY

SEQUENCE-DEPENDENT ENHANCEMENT OF PACLITAXEL TOXICITY IN NON–SMALL CELL LUNG CANCER BY 17-ALLYLAMINO 17-DEMETHOXYGELDANAMYCIN

From the Section of Thoracic Oncology, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Address for reprints: Dao M. Nguyen, MD, Senior Investigator, Thoracic Oncology Section, Surgery Branch, NCI/NIH, Room 2b07, Building 10, 10 Center Dr, Bethesda, MD 20892-1502 (E-mail:Dao_Nguyen{at}nih.gov).

Objective: Overexpression of the oncogene erbB-2 contributes to chemoresistance in various malignant tumors including lung cancer. The aim of this study was to investigate whether depletion of the erbB-2 gene product (p185) by 17-allylamino 17-demethoxygeldanamycin would sensitize lung cancer cells to paclitaxel (Taxol) in vitro.
Methods: Paclitaxel cytotoxicity was evaluated in a panel of non–small cell lung cancer cell lines that expressed varying levels of p185 by means in vitro proliferation assays and 2 drug combination schedules. Cell cycle kinetics and apoptosis after exposure to paclitaxel or paclitaxel plus 17-allylamino 17-demethoxygeldanamycin were analyzed by flow cytometry.
Results: The 17-allylamino 17-demethoxygeldanamycin treatment efficiently depleted p185 expression in lung cancer cells. Concurrent exposure of these cells to paclitaxel and 17-allylamino 17-demethoxygeldanamycin significantly enhanced paclitaxel-mediated cytotoxicity, particularly in cells which overexpressed p185. There was a 1.3 to more than 20-fold reduction of paclitaxel 50% inhibitory concentration values in those cells that were responding positively to the drug combination. Significant induction of apoptosis was observed after treatment of cells with the combination of paclitaxel and 17-allylamino 17-demethoxygeldanamycin. The combination cytotoxic effect was only additive in cells expressing low levels of p185. In contrast, of lung cancer cells with exposure to 17-allylamino 17-demethoxygeldanamycin before combined paclitaxel and 17-allylamino 17-demethoxygeldanamycin exposure actually rendered the cells refractory to paclitaxel cytotoxicity.
Conclusion: The compound 17-allylamino 17-demethoxygeldanamycin sensitizes non–small cell lung cancer cells expressing high levels of p185 to paclitaxel-mediated growth arrest and apoptosis. These preclinical data support the evaluation of the combination of paclitaxel and 17-allylamino 17-demethoxygeldanamycin in the treatment of patients with lung cancer whose tumors exhibit p185 overexpression.

This article has been cited by other articles:

				S. S. Ramalingam, M. J. Egorin, R. K. Ramanathan, S. C. Remick, R. P. Sikorski, T. F. Lagattuta, G. S. Chatta, D. M. Friedland, R. G. Stoller, D. M. Potter, et al. A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3456 - 3461. [Abstract] [Full Text] [PDF]

				A. Sawai, S. Chandarlapaty, H. Greulich, M. Gonen, Q. Ye, C. L. Arteaga, W. Sellers, N. Rosen, and D. B. Solit Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel Cancer Res., January 15, 2008; 68(2): 589 - 596. [Abstract] [Full Text] [PDF]

				N. Sain, B. Krishnan, M. G. Ormerod, A. De Rienzo, W. M. Liu, S. B. Kaye, P. Workman, and A. L. Jackman Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol. Cancer Ther., May 1, 2006; 5(5): 1197 - 1208. [Abstract] [Full Text] [PDF]

				T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins Cancer Res., July 15, 2005; 65(14): 6401 - 6408. [Abstract] [Full Text] [PDF]

				G. de Carcer Heat Shock Protein 90 Regulates the Metaphase-Anaphase Transition in a Polo-Like Kinase-Dependent Manner Cancer Res., August 1, 2004; 64(15): 5106 - 5112. [Abstract] [Full Text] [PDF]

				R. Enmon, W.-H. Yang, A. M. Ballangrud, D. B. Solit, G. Heller, N. Rosen, H. I. Scher, and G. Sgouros Combination Treatment with 17-N-Allylamino-17-Demethoxy Geldanamycin and Acute Irradiation Produces Supra-Additive Growth Suppression in Human Prostate Carcinoma Spheroids Cancer Res., December 1, 2003; 63(23): 8393 - 8399. [Abstract] [Full Text] [PDF]

				I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer Geldanamycin and its 17-Allylamino-17-Demethoxy Analogue Antagonize the Action of Cisplatin in Human Colon Adenocarcinoma Cells: Differential Caspase Activation as a Basis for Interaction Cancer Res., June 15, 2003; 63(12): 3241 - 3246. [Abstract] [Full Text] [PDF]

				D. S. Schrump, S. Zhai, D. M. Nguyen, T. S. Weiser, B. A. Fisher, R. E. Terrill, B. M. Flynn, P. H. Duray, and W. D. Figg Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 686 - 694. [Abstract] [Full Text] [PDF]

				D. M. Nguyen, D. Lorang, G. A. Chen, J. H. Stewart IV, E. Tabibi, and D. S. Schrump Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Ann. Thorac. Surg., August 1, 2001; 72(2): 371 - 379. [Abstract] [Full Text] [PDF]

				J. Yang, J.-M. Yang, M. Iannone, W. J. Shih, Y. Lin, and W. N. Hait Disruption of the EF-2 Kinase/Hsp90 Protein Complex: A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin Cancer Res., May 1, 2001; 61(10): 4010 - 4016. [Abstract] [Full Text]

				D. M. Nguyen, S. Desai, A. Chen, T. S. Weiser, and D. S. Schrump Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin Ann. Thorac. Surg., December 1, 2000; 70(6): 1853 - 1860. [Abstract] [Full Text] [PDF]